The 2011 UPS “Pain in the (Supply) Chain” survey explores top business and supply chain concerns at pharmaceutical, biotech and medical device companies worldwide. Findings show changes in healthcare legislation, reform and intellectual property protection are major concerns as the industry’s pace accelerates globally. View Report.
Product Class Quality, Bioassays, Regulatory Issues Related to Monoclonal Antibodies, Cell Therapies, and Other Biologics to Be Addressed
Rockville, Md., September 6, 2011 — Increasingly used to treat certain advanced-stage cancers, chronic inflammatory diseases, and complex disorders such as cystic fibrosis, biologic and biotechnology products are providing answers to some of the unmet needs for a growing list of diseases. Collectively referred to as “biologics,” these therapies are also being used in some cases where traditional medical treatments are no longer viable options for patients. This year, the U.S. Pharmacopeial Convention (USP) will dedicate its annual scientific symposium to the important area of quality standards for biologic and biotechnology-based drugs.
Click here to view
The following videos provide highlights of the 2011 USP Science & Standards Symposium on Biologics & Biotechnology, "Advancing Quality Standards through Analytics & Assays," October 3-6, 2011, in Seattle.
For event information, visit: http://www.usp.org/meetings/asMeetingIntl/seattleEvent.html.
For anyone who will be attending the USP conference, so will I - on behalf of Life Science Leader. Please feel free to contact me regarding the event through the editors, LinkedIn or directly,
Want more? Visit...